D. Shand

发表

Effects of age and cigarette smoking on propranolol disposition

R. Branch, R. Vestal, G. Wilkinson, 1979, Clinical pharmacology and therapeutics.

Effects of caffeine on plasma renin activity, catecholamines and blood pressure.

D Robertson, J. Oates, D. Robertson, 1978, The New England journal of medicine.

A physiological approach to hepatic drug clearance

Grant R. Wilkinson, G. Wilkinson, D. Shand, 1975 .

The ability of vascular tissue to produce prostacyclin decreases with age.

R. S. Kent, A. Whorton, D. Shand, 1981, Prostaglandins.

Plasma Propranolol Levels in the Quantitative Assessment of β-adrenergic Blockade in Man

D. Shand, D. Coltart, 1970, British medical journal.

Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination

R. Branch, R. Vestal, G. Wilkinson, 1979, Clinical pharmacology and therapeutics.

The reduction of lidocaine clearance by dl-propranolol: an example of hemodynamic drug interaction.

R. Branch, G. Wilkinson, D. Shand, 1973, The Journal of pharmacology and experimental therapeutics.

Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance.

G R Wilkinson, A. Rane, G. Wilkinson, 1977, The Journal of pharmacology and experimental therapeutics.

Presystemic drug metabolism in the liver

C. George, D. Shand, 1982 .

Impaired drug metabolism in experimental cirrhosis in the rat.

R. Branch, J. Villeneuve, A. Wood, 1978, Biochemical pharmacology.

Biological determinants of propranolol disposition in man

R. Branch, R. Vestal, G. Wilkinson, 1978, Clinical pharmacology and therapeutics.

Comparison of high-dose and medium-dose propranolol in the relief of exercise-induced myocardial ischemia.

R. Coleman, M. Higginbotham, F. Cobb, 1983, The American journal of cardiology.

How should the proper dose of a beta blocker be determined?

D. Shand, 1983, Circulation.

Disposition of propranolol V. Drug accumulation and steady‐state concentrations during chronic oral administration in man

D. Shand, G. H. Evans, Gwyn H. Evans, 1973, Clinical pharmacology and therapeutics.

Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs.

D. Shand, 1974, Drugs.

Plasma concentrations and the time‐course of beta blockade due to propranolol

D. Shand, D. McDevitt, 1975, Clinical pharmacology and therapeutics.

PLASMA CONCENTRATIONS AND THE TIME-COURSE OF BETA BLOCKADE DUE TO PROPRANOLOL

D. Shand, D. McDevitt, 1976 .

Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen.

E. Pritchett, M. Reiter, D. Shand, 1982, The American journal of cardiology.

Drug disposition in liver disease.

D. Shand, 1977, The New England journal of medicine.

Time required for complete recovery from chronic propranolol therapy.

J. Young, R. Boerth, H. Bender, 1973, The New England journal of medicine.

Evidence for cardiac β2‐adrenoceptors in man

D. Shand, James E. Brown, A. A. Mcleod, 1983 .

Reduced β‐adrenoceptor sensitivity in the elderly

R. Vestal, A. Wood, D. Shand, 1979 .

The disposition of propranolol. I. Elimination during oral absorption in man.

D. Shand, R. Rangno, 1972, Pharmacology.

Suppression of Chronic Ventricular Arrhythmias with Propranolol

J. Oates, R. Woosley, D. Shand, 1979, Circulation.

Further Observations on Relationships between Antipyrine Half-life, Clearance and Volume of Distribution: An Appraisal of Alternative Kinetic Parameters Used to Assess the Elimination of Antipyrine

R. Branch, B. Dvorchik, L. Sultatos, 1980, Clinical pharmacokinetics.

The Disposition of Propranolol

D. Shand, R. Rangno, G. H. Evans, 1972 .

Perfusion-limited effects of plasma drug binding on hepatic drug extraction

G. Wilkinson, D. Shand, R. Cotham, 1976 .

Perfusion-limited of plasma drug binding on hepatic drug extraction.

G. Wilkinson, D. Shand, R. Cotham, 1976, Life sciences.

Beta 1-selective and non-selective beta-adrenoceptor blockade, anaerobic threshold and respiratory gas exchange during exercise.

R. S. Williams, D. Shand, A. A. Mcleod, 1985, British journal of clinical pharmacology.

Estimation of kinetic parameters from a two‐point determination of the drug cumulation factor

T. Bjornsson, D. Shand, 1979, Clinical pharmacology and therapeutics.

Pharmacokinetics of antiarrhythmic drugs.

R. Woosley, D. Shand, Raymond L. Woosley, 1978, The American journal of cardiology.

Presystemic hepatic drug elimination in cirrhosis

D. Shand, 1982 .

Propranolol Disposition in Chronic Liver Disease: A Physiological Approach

R. Branch, D. Shand, 1976, Clinical pharmacokinetics.

Clinical Pharmacology of Propranolol

D. Shand, A. Nies, 1975, Circulation.

Comparative Assessment of Stimuli That Release Neuronal and Adrenomedullary Catecholamines in Man

J. Oates, D. Robertson, D. Shand, 1979, Circulation.

Plasma Norepinephrine in the Evaluation of Baroreceptor Function in Humans

J. Gunnells, D. Shand, S. Grossman, 1982, Hypertension.

Differentiation of Hemodynamic, Humoral and Metabolic Responses to β1‐ and β2‐adrenergic Stimulation in Man Using Atenolol and Propranolol

R. S. Williams, D. Shand, F. Sedor, 1983 .

The sympathetic response to profound hypothermia and circulatory arrest in infants

A. Wood, M. Wood, D. Shand, 1980, Canadian Anaesthetists' Society journal.

Proposed mechanisms of propranolol's antihypertensive effect in essential hypertension.

D. Shand, J. Hollifield, R. V. Zwagg, 1976, The New England journal of medicine.

Individualization of propranolol therapy.

D. Shand, 1974, The Medical clinics of North America.

Alterations in the Responses of the Sympathetic Nervous System and Renin in Borderline Hypertension

J. Oates, D. Robertson, D. Shand, 1979, Hypertension.

Effects of route of administration and blood flow on hepatic drug elimination.

G. Wilkinson, D. Shand, D. Kornhauser, 1975, The Journal of pharmacology and experimental therapeutics.

Effect of Cetamolol on Epinephrine‐Induced Hypokalemia

G. Wagner, N. B. Wagner, C. Irwin, 1988, Journal of clinical pharmacology.

A standardized isoproterenol sensitivity test. The effects of sinus arrhythmia, atropine, and propranolol.

D. Shand, R. Rangno, C. Cleaveland, 1972, Archives of internal medicine.

Reduced beta-adrenoceptor sensitivity in the elderly.

R. Vestal, A. Wood, D. Shand, 1979, Clinical pharmacology and therapeutics.

Interaction of topical and oral timolol in glaucoma.

A. Wood, D. Shand, D. O'day, 1979, Ophthalmology.

Altered drug binding due to the use of indwelling heparinized cannulas (heparin lock) for sampling

A. Wood, M. Wood, D. Shand, 1979, Clinical pharmacology and therapeutics.

Metabolism of propranolol by rat liver microsomes and its inhibition by phenothiazine and tricyclic antidepressant drugs.

J. Oates, J. Oates, D. Shand, 1971, Biochemical pharmacology.

Therapeutic Drug Monitoring of Antiarrhythmic Agents

D. Shand, J. Brown, James E. Brown, 1982, Clinical pharmacokinetics.

Effect of route of administration on the relationship between β‐adrenergic blockade and plasma propranolol level

D. Shand, Clifton R. Cleaveland, 1972, Clinical pharmacology and therapeutics.

Plasma Propranolol Levels Associated with Suppression of Ventricular Ectopic Beats

D. Shand, D. Coltart, D. Gibson, 1971, British medical journal.

Editorial: Propranolol Withdrawal Syndrome Why?

A. Wood, D. Shand, 1978, Circulation.

Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats.

W. Kaelin, R. Jirtle, S. Shrivastav, 1982, Cancer research.

In support of cardiac chronotropic beta 2 adrenoceptors.

D. Shand, J. Brown, A. A. Mcleod, 1986, The American journal of cardiology.

Pharmacokinetic and pharmacodynamic effects of diltiazem.

E. Pritchett, D. Shand, B. R. Brown, 1983, The American journal of cardiology.

Drug therapy: Propranolol.

D. Shand, 1975, The New England journal of medicine.

Differentiation of hemodynamic, humoral and metabolic responses to beta 1- and beta 2-adrenergic stimulation in man using atenolol and propranolol.

R. S. Williams, D. Shand, F. Sedor, 1983, Circulation.

Direct measurement of propranolol bioavailability during accumulation to steady-state.

R. Vestal, G. Wilkinson, A. Wood, 1978, British journal of clinical pharmacology.

DISTRIBUTION OF GUANIDINIUM ANTIHYPERTENSIVES—MECHANISM OF THEIR SELECTIVE ACTION *

J. Oates, D. Shand, J. Mitchell, 1971, Annals of the New York Academy of Sciences.

Prostaglandins and renin release: II. Assessment of renin secretion following infusion of PGI2,E2 and D2 into the renal artery of anesthetized dogs.

R. Branch, J. Oates, J. Gerber, 1978, Prostaglandins.

Reduction of Plasma Renin Activity by Inhibition of the Fatty Acid Cyclooxygenase in Human Subjects: Independence of Sodium Retention

J. Oates, A. Michelakis, D. Shand, 1979, Circulation research.

Presystemic drug elimination.

P. Routledge, D. Shand, 1979, Annual review of pharmacology and toxicology.

TIMOLOL MALEATE—A PROMISING NEW BETA ADRENERGIC BLOCKER FOR GLAUCOMA

A. Wood, D. Shand, D. O'day, 1979 .

Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat.

R. Branch, J. Villeneuve, A. Wood, 1979, Gastroenterology.

Comparison of intravenous and oral verapamil dosing

E. Pritchett, M. Reiter, D. Shand, 1982, Clinical pharmacology and therapeutics.

The disposition of propranolol. 8. General implications of the effects of liver blood flow on elimination from the perfused rat liver.

R. Branch, D. Shand, A. Nies, 1973, Drug metabolism and disposition: the biological fate of chemicals.

Regional hemodynamic effects of beta-adrenergic blockade with propranolol in the unanesthetized primate.

D. Shand, A. Nies, G. H. Evans, 1973, American heart journal.

Determinants of plasma a ,-acid glycoprotein ( AAG ) concentrations in health

P. Blain, J. Mucklow, M. Rawlins, 2006 .

Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health.

P. Blain, J. Mucklow, M. Rawlins, 1985, British journal of clinical pharmacology.

Pharmacokinetic Drug Interactions

J. Oates, D. Shand, Jerry R. Mitchell, 1975 .

Antenolol: A Long-Acting Beta1-Adrenoceptor Antagonist

D. Shand, A. A. Mcleod, 1982 .

The almost complete hepatic extraction of propranolol during intravenous administration in the dog.

D. Shand, A. Nies, G. H. Evans, 1971, Life sciences. Pt. 1: Physiology and pharmacology.

Determinants ofplasmaa,-acid glycoprotein (AAG) concentrations inhealth

P. Blain, J. Mucklow, M. Rawlins, 1985 .

Spuriously low plasma propranolol concentrations resulting from blood collection methods

D. Shand, R. Cotham, 1975, Clinical pharmacology and therapeutics.

Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction.

G. Wagner, P. Routledge, D. Shand, 1980, Annals of internal medicine.

A comparison of the pulmonary, renal and hepatic extractions of PGI2 and PGE2 - PGI2 a potential circulating hormone.

R. Branch, J. Gerber, D. Shand, 1978, Life sciences.

Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat.

R. Branch, J. Villeneuve, A. Wood, 1979, Gastroenterology.

Plasma binding and the affinity of propranolol for a beta receptor in man

D. Shand, J. Hollifield, D. McDevitt, 1976, Clinical pharmacology and therapeutics.

Lidocaine plasma protein binding

T. Bjornsson, P. Routledge, A. Barchowsky, 1980, Clinical pharmacology and therapeutics.

Hemodynamic and metabolic responses to exercise after alpha 1-, beta 1-, and nonselective beta-adrenoceptor blockade in man.

R. S. Williams, D. Shand, F. Sedor, 1984, The American journal of medicine.

Altered Hepatic Blood Flow and Drug Disposition

G. Wilkinson, D. Shand, A. Nies, 1976, Clinical pharmacokinetics.

Hepatic circulation and drug disposition in cirrhosis.

D. Shand, 1979, Gastroenterology.

The Effect of Etodolac Administration on Renal Function in Patients With Arthritis

J. Mullane, M. Sanda, D. Shand, 1986, Journal of clinical pharmacology.

Effect of PGI2, PGE2 and 6-keto PGF1α on canine gastric blood flow and acid secretion

R. Branch, J. Gerber, D. Shand, 1978 .

The disposition of propranolol. IV. A dominant role for tissue uptake in the dose-dependent extraction of propranolol by the perfused rat liver.

G. Wilkinson, D. Shand, G. H. Evans, 1973, The Journal of pharmacology and experimental therapeutics.

Effect of indomethacin and aspirin on gastric blood flow and acid secretion.

C. Flexner, J. Oates, D. Shand, 1977, The Journal of pharmacology and experimental therapeutics.

Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.

R. Branch, G. Wilkinson, D. Shand, 1974, The Journal of clinical investigation.

The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol.

D. Shand, A. Nies, G. H. Evans, 1973, The Journal of pharmacology and experimental therapeutics.

Human safety profile of tolrestat: An aldose reductase inhibitor

J. Mullane, D. Shand, S. Ryder, 1987 .

The Influence of Cirrhosis on Steady-State Blood Concentrations of Unbound Propranolol after Oral Administration

R. Branch, G. Wilkinson, A. Wood, 1978, Clinical pharmacokinetics.

Propranolol Binding in Plasma during Cardiopulmonary Bypass

A. Wood, M. Wood, D. Shand, 1979, Anesthesiology.

The artifactual nature of heparin‐induced drug protein‐binding alterations

T. Bjornsson, D. Shand, B. Kitchell, 1981, Clinical pharmacology and therapeutics.

Propranolol disposition in renal failure.

R. Vestal, G. Wilkinson, A. Wood, 1980, British journal of clinical pharmacology.

Proceedings: High-affinity hepatic microsomal binding of propranolol: its relationship to metabolism and to the first-pass effect.

G. Wilkinson, D. Shand, J. Mcewen, 1974, British journal of pharmacology.

Plasma propranolol levels in adults With observations in four children

J. Oates, D. Shand, D G Shand, 1970, Clinical pharmacology and therapeutics.

The method of separate exponentials: A simple aid to devising intravenous drug‐loading regimens

E. Pritchett, S. Hammill, T. Bjornsson, 1981, Clinical pharmacology and therapeutics.

The Clinical Pharmacology of Antihypertensive Drugs

J. Oates, D. Shand, B. Prichard, 1977 .

Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice.

M. Steiert, J. Talmadge, S. Barry, 2005, International journal of pharmaceutics.

Clinical Pharmacokinetics of Propranolol

P. Routledge, D. Shand, 1979, Clinical pharmacokinetics.

A radioreceptor assay for propranolol

J. Bilezikian, D. Shand, D. Gammon, 1979, Clinical pharmacology and therapeutics.

Hemodynamic and metabolic responses to exercise after adrenoceptor blockade in humans.

R. S. Williams, D. Shand, F. Sedor, 1984, Journal of applied physiology: respiratory, environmental and exercise physiology.

Commentary: a physiological approach to hepatic drug clearance.

G R Wilkinson, G. Wilkinson, D. Shand, 1975, Clinical pharmacology and therapeutics.

High-performance liquid chromatographic analysis of diltiazem and its metabolite in plasma.

E. Pritchett, D. Shand, L. Aanonsen, 1983, Journal of chromatography.

Influence of cimetidine on verapamil kinetics and dynamics

E. Pritchett, T. Bjornsson, M. Benyunes, 1984, Clinical pharmacology and therapeutics.

Verapamil plasma binding: relationship to alpha 1-acid glycoprotein and drug efficacy.

E. Pritchett, F. McGowan, M. Reiter, 1983, Clinical pharmacology and therapeutics.

Inhibition of propranolol metabolism by chlorpromazine

R. Vestal, D. Shand, J. Hollifield, 1979, Clinical pharmacology and therapeutics.

Relation between residual urine volume and response to treatment of urinary infection.

D. Shand, F. O'grady, W. Cattell, 1970, The Lancet.

Estimation of residual urine volume with 131 I-hippuran.

D. Shand, W. Cattell, J. C. Mackenzie, 1968, British journal of urology.

Pharmacokinetic Properties of the β-Adrenergic Receptor Blocking Drugs

D. Shand, 2012, Drugs.

Control of lidocaine therapy: new perspectives.

G. Wagner, P. Routledge, A. Barchowsky, 1982, Therapeutic drug monitoring.

Actions of gallamine and tetraethylammonium at the frog neuromuscular junction.

D. Shand, B. W. Payton, 1966, British journal of pharmacology and chemotherapy.

Clinical comparison of rapid infusion and multiple injection methods for lidocaine loading.

G. Wagner, P. Routledge, A. Barchowsky, 1981, American heart journal.

On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction.

G. Wagner, P. Routledge, A. Barchowsky, 1982, British journal of clinical pharmacology.

ON THE ROLE OF aI -ACID GLYCOPROTEIN IN LIGNOCAINE ACCUMULATION FOLLOWING MYOCARDIAL INFARCTION

G. Wagner, A. Barchowsky, D. Shand, 2006 .

The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.

D. Shand, A. Nies, G. H. Evans, 1973, The Journal of pharmacology and experimental therapeutics.

Disposition of propranolol VI. Independent variation in steady‐state circulating drug concentrations and half‐life as a result of plasma drug binding in man

D. Shand, Gwyn H. Evans, 1973, Clinical pharmacology and therapeutics.

α1-Acid Glycoprotein and Plasma Lidocaine Binding

D. Shand, 1984 .

Lidocaine and Its Metabolites in Canine Plasma and Myocardium

T. Wenger, H. Strauss, A. Barchowsky, 1983, Journal of cardiovascular pharmacology.

Importance of blood-collection tubes in plasma lidocaine determinations.

C. Roe, P. Routledge, D. Shand, 1979, Clinical chemistry.

Clinical comparison of raipid infusion and mwltipk injection meth& for lidocaine loading

G. Wagner, P. Routledge, A. Barchowsky, 1981 .

P. Routledge, A. Barchowsky, D. Shand, 1981, British journal of clinical pharmacology.

Disposition of propoxyphene and propranolol in children

G. Atwood, John T. Wilson, D. Shand, 1976, Clinical pharmacology and therapeutics.

Diazepam and lidocaine plasma protein binding in renal disease

P. Routledge, D. Shand, B. Kitchell, 1982, Clinical pharmacology and therapeutics.

PHARMACOKINETICS OF THE FIRST PASS EFFECT

G. Wilkinson, D. Shand, A. Nies, 1976 .

Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction.

G. Wagner, P. Routledge, A. Barchowsky, 1981, Clinical pharmacology and therapeutics.

Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction.

G. Wagner, P. Routledge, A. Barchowsky, 1989, British journal of clinical pharmacology.

The effects of age and smoking on the plasma protein binding of lignocaine and diazepam.

P. Routledge, D. Shand, B. Kitchell, 1985, British journal of clinical pharmacology.

A free lignocaine index as a guide to unbound drug concentration.

G. Wagner, P. Routledge, A. Barchowsky, 1985, British journal of clinical pharmacology.

Relationship between α1‐acid glycoprotein and lidocaine disposition in myocardial infarction

G. Wagner, P. Routledge, A. Barchowsky, 1981 .

Hemodynamic drug interactions: the reduction of oxyphenbutazone clearance by dl-propranol in the dog.

R. Branch, D. Shand, A. Nies, 1973, The Journal of pharmacology and experimental therapeutics.

Drug/Drug Interactions and the Delivery of Drugs to their Site of Action—Important Clinical Aspects

D. Shand, 1972 .

Hypertrophic obstructive cardiomyopathy in an infant--propranolol therapy for three years.

J. Oates, D. Shand, C. G. Sell, 1971, The New England journal of medicine.

Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia.

K. Lee, E. Pritchett, S. Hammill, 1983, The American journal of cardiology.

Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies.

G. Stiles, D. Shand, A. A. Mcleod, 1984, The Journal of pharmacology and experimental therapeutics.

State-of-the-Art: Comparative Pharmacology of the β-Adrenoceptor Blocking Drugs

D. Shand, 1983, Drugs.

Rapid high-performance liquid chromatographic method for the measurement of atenolol in plasma using UV detection.

D. Shand, A. Mcleod, C. Verghese, 1983, Journal of chromatography.

Biological determinants of altered pharmacokinetics in the elderly.

D. Shand, 1982, Gerontology.

Regional hemodynamic effects of dopamine in the unanesthetized primate: failure to alter flow-dependent hepatic drug clearance.

R. Branch, D. Shand, A. Nies, 1973, European journal of pharmacology.

alpha 1-Acid glycoprotein and plasma lidocaine binding.

D. Shand, 1984, Clinical pharmacokinetics.

A Re-evaluation of Intersubject Variation in Enzyme Induction in Man

R. Branch, D. Shand, 1979, Clinical pharmacokinetics.

Drug metabolism in rats bearing a pituitary mammotropic tumor.

J. T. Wilson, R. Branch, J. Villeneuve, 1979, The Journal of pharmacology and experimental therapeutics.

Heparin administration increases plasma warfarin binding in man.

T. Bjornsson, P. Routledge, D. Shand, 1979, British journal of clinical pharmacology.

Clinical pharmacology of the beta-blocking drugs: implications for the postinfarction patient.

D. Shand, 1983, Circulation.

Reduced verapamil clearance during long‐term oral administration

E. Pritchett, S. Hammill, D. Shand, 1981, Clinical pharmacology and therapeutics.

Prostaglandin and histamine involvement in the gastric vasodilator action of pentagastrin.

C. Flexner, J. Oates, D. Shand, 1977, The Journal of pharmacology and experimental therapeutics.

Hypertensive response to propranolol in a patient treated with methyldopa—a proposed mechanism

D. Shand, A. Nies, 1973, Clinical pharmacology and therapeutics.

The disposition of propranolol. VII. The effects of saturable hepatic tissue uptake on drug clearance by the perfused rat liver.

R. Branch, G. Wilkinson, D. Shand, 1973, Drug metabolism and disposition: the biological fate of chemicals.

Propranolol decreases serum thyroxine as well as triiodothyronine in rats: a protein-binding effect.

R. Smallridge, P. Routledge, L. Wartofsky, 1983, Endocrinology.

Increased plasma propranolol binding in myocardial infarction.

G. Wagner, P. Routledge, D. Shand, 1980, British journal of clinical pharmacology.

Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings].

R. Branch, G. Wilkinson, A. Wood, 1977, British journal of clinical pharmacology.

Active uptake of propranolol by isolated rabbit alveolar macrophages and its inhibition by other basic amines.

R. Vestal, D. Shand, D. Kornhauser, 1980, The Journal of pharmacology and experimental therapeutics.

Uptake of propranolol by the lung and its displacement by other drugs: involvement of the alveolar macrophage.

R. Vestal, D. Shand, D G Shand, 1980, Pharmacology.

Lignocaine disposition in blood in epilepsy.

A. Finn, P. Routledge, A. Barchowsky, 1981, British journal of clinical pharmacology.

Pirmenol, A New Antiarrhythmic Agent: Initial Study of Efficacy, Safety and Pharmacokinetics

E. Pritchett, S. Hammill, P. Routledge, 1982, Circulation.

The disposition of propranolol. II. Hepatic elimination in the rat.

D. Shand, R. Rangno, G. H. Evans, 1972, Pharmacology.

The release of guanethidine and bethanidine by splenic nerve stimulation: a quantitative evaluation showing dissociation from adrenergic blockade.

J. Oates, D. Shand, D. H. Morgan, 1973, The Journal of pharmacology and experimental therapeutics.

THE SELECTIVITY OF DRUGS BLOCKING GANGLIONIC TRANSMISSION IN THE RAT.

J. P. Quilliam, D. Shand, 1964, British journal of pharmacology and chemotherapy.

A loading‐maintenance regimen for more rapid initiation of the effect of guanethidine

J. Oates, D. Shand, A. Nies, 1975 .

Adrenergic control of tendon jerk reflexes in man

A. Richens, D. Shand, S. Phillips, 1973, British journal of pharmacology.

High-performance liquid chromatographic analysis of sulfinpyrazone and its metabolites in biological fluids.

T. Bjornsson, P. Routledge, D. Shand, 1980, Journal of chromatography.

EFFECTS OF CAFFEINE ON PLASMA RENIN ACTIVITY, CATECHOLAMINES AND BLOOD PRESSURE

J. Oates, D. Robertson, J. Watson, 1978 .

Dose proportionality comparison of beta1 blocking activity of cetamolol hydrochloride and atenolol in normal subjects

D. Dvornik, J. Mullane, C. Perdomo, 1984 .

Effects of Concentration and Steric Configuration of Propranolol on AV Conduction and Ventricular Repolarization in the Dog

R. Woosley, L. Brorson, D. Shand, 1981, Journal of Cardiovascular Pharmacology.

Saliva Concentrations of Lidocaine and Its Metabolites in Man

P. Routledge, A. Barchowsky, D. Shand, 1982, Therapeutic drug monitoring.

Efficacy, safety, and pharmacokinetics of a concentration-maintaining regimen of intravenous pirmenol.

E. Pritchett, S. Hammill, M. Reiter, 1983, The American journal of cardiology.

Pirmenol kinetics and effective oral dose

F. Harrell, E. Pritchett, S. Hammill, 1982, Clinical pharmacology and therapeutics.

Increase in hepatic blood flow and d-propranolol clearance by glucagon in the monkey.

R. Branch, D. Shand, A. Nies, 1973, The Journal of pharmacology and experimental therapeutics.

Verapamil plasma binding: Relationship to α1‐acid glycoprotein and drug efficacy

E. Pritchett, F. McGowan, M. Reiter, 1983 .

Therapeutic Drug Monitoring of Antiarrhythmic Agents

D. Shand, James E. Brown, 1982, Clinical pharmacokinetics.

Antiarrhythmic effects of the quaternary propranolol analog that does not induce beta‐adrenergic blockade

J. Oates, R. Woosley, D. Shand, 1982, Clinical pharmacology and therapeutics.

PHARMACOKINETIC STUDIES: THEIR ROLE IN DETERMINING THERAPEUTIC EFFICACY OF AGENTS DESIGNED TO PREVENT SUDDEN DEATH *

G. Wagner, S. Hammill, D. Shand, 1982, Annals of the New York Academy of Sciences.

Diazepam and lidocaine plasma protein binding in renal disease

P. Routledge, D. Shand, B. Kitchell, 1982, Clinical pharmacology and therapeutics.

Pharmacokinetics of propranolol: a review.

D. Shand, 1976, Postgraduate medical journal.

CLINICAL PHARMACOLOGY OF PROPRANOLOL animals

D. Shand, A. Nies, M. One, 2005 .

Diazepam and N‐desmethyldiazepam redistribution after heparin

T. Bjornsson, M. Linnoila, P. Routledge, 1980, Clinical pharmacology and therapeutics.

Hemodynamic drug interactions.

R. Branch, D. Shand, A. Nies, 1974, Cardiovascular clinics.

Evidence for cardiac beta 2-adrenoceptors in man.

D. Shand, J. Brown, A. A. Mcleod, 1983, Clinical pharmacology and therapeutics.